Isabel Kallman, 53, experiences perimenopause symptoms and considers hormone therapy (HT). Concerns about HT's risks, stemming from a flawed 2002 study, have lingered. However, recent research suggests that age at treatment start and dosage significantly impact safety. Doctors now emphasize individualized risk assessment and tailored treatment plans, often involving low-dose options. While the FDA considers altering HT warnings, some experts urge caution, demanding more data before label changes.

Prepared by Olivia Bennett and reviewed by editorial team.